Odatroltide

(May 14, 2024, Taipei) Lumosa Therapeutics Co., Ltd. (Lumosa; code:6535.TWO) today held an institutional investors' conference and announced the Board's resolutions for a new equity financing round and key management changes. Ms. Su-Chi Wang, the representative nominated by Lumosa's largest shareholder Center Laboratories Group, has been appointed as the new Chairman of the Board. Dr. Sheng-Wen Yeh from the Preclinical Development Division will assume the role of General Manager, while the former Chairman and General Manager Mr. Rong-Jin Lin is stepping down temporarily to focus on strategic initiatives. As Lumosa's lead stroke therapy LT3001 approaches a critical juncture for global licensing, Mr. Lin will leverage his expansive network across Center Laboratories Group's international pharmaceutical investment portfolio to maximize LT3001's worldwide commercialization prospects. The new General Manager Dr. Sheng-Wen Yeh has been the driving force behind LT3001's development from compound selection, preclinical validation, mechanism elucidation to clinical trial design over the past decade. She will apply her product expertise to execute a de-risked clinical strategy and ensure the pivotal studies achieve their endpoints. With the Group's licensing capabilities, Lumosa aims to unlock LT3001's full value proposition. "Establishing a top 50 global pharmaceutical company from Taiwan has been my lifelong mission," said Mr. Lin. "Now that LT3001 has reached an important inflection point, I will marshal the Group's resources to clear the path for its global licensing. Dr. Yeh is undoubtedly the world's foremost scientific authority on LT3001 and the ideal person to lead Lumosa. I look forward to our licensingt and clinical initiatives converging to complete LT3001's final step onto the world stage." In today's institutional investors' conference, Dr. Sheng-Wen Yeh provided updates on the key pipeline programs: For the three pivotal Phase 2 studies of LT3001 underway, patient enrollment in the China study conducted by regional partner Shanghai Pharmaceutical Holdings has exceeded expectations, with over 80% of the target number of patients already enrolled. Last Patient In (LPI) is expected in mid-2024, keeping the study on track for data readout by year-end. The two global studies led by Lumosa are projected to complete in 2025. In parallel, Lumosa is actively investing in next-generation modalities beyond LT3001, spanning exosome and allogeneic cell therapies. The Company recently invested in the innovative gene editing firm GenEditBio to enter the gene therapy space, exploring various emerging therapeutic platforms. Lumosa's marketed long-acting analgesic LT1001 has obtained marketing approvals across six countries to date and will continue to pursue niche market opportunities to provide financial optionality. Looking ahead, successful LT3001 commercialization is expected to fuel the incubation of Lumosa's future innovative pipeline and reinforce its sustainable business model.

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-protecting effects into one treatment, potentially revolutionizing acute stroke therapy. Stroke, a leading cause of adult disability globally, hits particularly hard in Chattanooga, Tenn., an area known as the "Stroke Belt," with one of the highest incidences of stroke in the nation. LT3001 aims to extend the critical treatment time window to 24 hours, offering the potential to transform outcomes for countless stroke patients. Unlike the current U.S. FDA-approved drug, tissue plasminogen activator (t-PA), which must be administered within 4.5 hours after onset of stroke symptoms, Lumosa's LT3001 breaks down clots while also protecting delicate nerve tissues in the brain. This novel approach greatly extends the stroke treatment window to 24 hours, allowing potential treatment for many more stroke victims. Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment. Addressing a Critical Unmet Need CHI Memorial, home to Chattanooga Center for Neurologic Research, LLC (CCNR), serves as the coordinating center for all Lumosa stroke studies in the United States. Thomas Devlin, MD, PhD, who is the medical director of the CHI Memorial Neuroscience Institute, acts as the international principal investigator for both the Lumosa 203 and BRIGHT Phase 2b randomized placebo-controlled, double-blinded trials. These trials focus on two patient populations: those undergoing mechanical thrombectomy (203 study, NCT05198323) and those who do not (BRIGHT study, NCT05403866). Both trials address the critical unmet need for more effective stroke treatment. With more than 795,000 strokes annually in the U.S., LT3001's 24-hour treatment window could be a game-changer, especially for patients in rural areas and those with limited access to immediate care. One of the only two treatments, the mechanical thrombectomy surgery alone for large vessel occlusion stroke, is effective in less than 50% of patients. The other one, t-PA, with the strict 4.5-hour time window, limits the treatment to only about 12 percent of stroke victims nationally. LT3001's combined clot-dissolving and neuroprotective effects offer hope for significantly improved outcomes. LT3001 can be administered within 24 hours after stroke onset for smaller, medium, or larger strokes, in both large and smaller rural hospital emergency departments, greatly expanding access and reaching more patients within a broader timeframe. In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study. Lumosa's 203 and BRIGHT trials are anticipated to be completed in a year or two. For study 203, Lumosa has partnered with 10 medical centers in the U.S., with CHI Memorial being the only one in Tennessee. This groundbreaking initiative aims to redefine stroke treatment possibilities, offering new hope to individuals and families affected by this debilitating condition. Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide. Contact: Lumosa Therapeutics Todd Ban [email protected].tw SOURCE Lumosa Therapeutics Co., Ltd.; CHI Memorial